IFW

PATENT

Case Docket No. TRIPEP.056A
Date: May 18, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	:	Matti Sällberg
Appl. No.	:	10/773,628
Filed	:	February 5, 2004
For	:	GLYCOSYLATED SPECIFICITY EXCHANGERS
Examiner	:	Unassigned
Group Art Unit	:	Unassigned

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 18, 2004
(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement.

(X) A PTO Form 1449 with one hundred seventy-five (175), which are also enclosed in two boxes. Box one includes the U.S. and Foreign patents listed on the form PTO-1449 and box two includes the articles listed on the form PTO-1449.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

(X) Return prepaid postcard.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\ESF\ESF-7637.DOC
031704

INFORMATION DISCLOSURE STATEMENT

Applicant	:	Matti Sällberg
App. No.	:	10/773,628
Filed	:	February 5, 2004
For	:	GLYCOSYLATED SPECIFICITY EXCHANGERS
Examiner	:	Unassigned
Group Art Unit	:	Unassigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing one hundred seventy-five (175) references that are also enclosed in two boxes. Box one includes the U.S. and Foreign patens listed on the form PTO-1449, and box two includes the articles listed on the form PTO-1449.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 5/18/04

By: _____

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\ESF\ESF-7635.DOC
031704

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Matti Sällberg	
	FILING DATE February 5, 2004	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	2004/0001853	01/01/04	George et al.			
	2.	2003/0021789A1	01/30/03	Xu et al.			
	3.	2003/0044418 A1	03/06/03	Davis et al.			
	4.	2002/0025513 A1	02/28/02	Sällberg			
	5.	2002/0058247 A1	05/16/02	Sällberg			
	6.	4,169,138	09/25/79	Jonsson			
	7.	4,376,110	03/08/83	David et al.			
	8.	4,471,058	09/11/84	Smith et al.			
	9.	4,486,530	12/04/84	David et al.			
	10.	4,589,881	05/20/86	Pierschbacher et al.			
	11.	4,946,778	08/07/90	Ladner et al.			
	12.	5,091,513	02/25/92	Huston et al.			
	13.	5,175,096	12/29/92	Hook et al.			
	14.	5,189,015	02/23/93	Hook et al.			
	15.	5,196,510	03/23/93	Rodwell et al.			
	16.	5,260,189	11/09/93	Formoso et al.			
	17.	5,320,951	06/14/94	Hook et al.			
	18.	5,416,021	05/16/95	Hook et al.			
	19.	5,440,014	08/08/95	Hook et al.			
	20.	5,561,049	10/01/96	Vold et al.			
	21.	5,571,511	11/05/96	Fischer			
	22.	5,571,514	11/05/96	Hook et al.			
	23.	5,582,975	12/10/96	Milliman			
	24.	5,583,042	12/10/96	Roth			
	25.	5,601,830	02/11/97	Su et al.			
	26.	5,627,263	05/06/97	Ruoslahti et al.			
	27.	5,652,217	07/29/97	Hook et al.			

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	28.	5,700,928	12/23/97	Hodgson et al.			
	29.	5,766,857	06/16/98	Ruoslahti et al.			
	30.	5,766,591	06/16/98	Brown			
	31.	5,770,208	06/23/98	Fattom et al.			
	32.	5,770,702	06/23/98	Hook et al.			
	33.	5,776,712	07/07/98	Kuusela et al.			
	34.	5,789,549	08/04/98	Hook et al.			
	35.	5,840,846	11/24/98	Hook et al.			
	36.	5,843,774	12/01/98	Ginsberg			
	37.	5,846,536	12/08/98	Bissell et al.			
	38.	5,866,541	02/02/99	Hook et al.			
	39.	5,869,232	02/09/99	Sällberg			
	40.	5,888,738	03/30/99	Hendry			
	41.	5,929,220	07/27/99	Tong et al.			
	42.	5,942,606	08/24/99	Lal et al.			
	43.	5,955,078	09/21/99	Burnham et al.			
	44.	5,980,908	11/09/99	Hook et al.			
	45.	5,981,274	11/09/99	Tyrrell et al.			
	46.	6,008,341	12/28/99	Foster et al.			
	47.	6,030,613	02/29/00	Blumberg, et al.			
	48.	6,040,137	03/21/00	Sällberg			
	49.	6,046,040	04/04/00	Nishiguchi et al.			
	50.	6,066,648	05/23/00	Duggan et al.			
	51.	6,077,677	06/01/00	Hodgson et al.			
	52.	6,086,875	07/11/00	Blumberg, et al.			
	53.	6,086,895	07/11/00	Hook et al.			
	54.	6,087,330	07/11/00	Kogan et al.			

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	55.	6,090,388	07/18/00	Wang			
	56.	6,090,944	07/18/00	Hutchinson			
	57.	6,093,539	06/25/00	Maddon et al.			
	58.	6,245,895	06/12/01	Sällberg			
	59.	6,303,120	10/16/01	Danishefsky et al.			
	60.	6,417,324	07/09/02	Sällberg			
	61.	6,458,937	10/01/02	Bertozzi et al.			
	62.	6,469,143	10/22/02	Sällberg			
	63.	6,485,726 B1	11/26/02	Blumberg, et al.			
	64.	6,660,842	12/09/03	Sällberg			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	65.	0 182 546 A2	05/28/86	EPO				
	66.	0 508 427 A	10/14/92	EPO				
	67.	WO 02/24887	03/28/02	WIPO				
	68.	WO 01/81421	11/01/01	WIPO				
	69.	WO 00/66621	11/09/00	WIPO				
	70.	WO 00/26385 A	05/11/00	PCT				
	71.	WO 99/61041 A	12/02/99	PCT				
	72.	WO 99/27109	06/3/99	PCT				
	73.	WO 98/31389	07/23/98	PCT				
	74.	WO 98/03543	01/29/98	WIPO				
	75.	WO 95/22249 A	08/24/95	PCT				
	76.	WO 95/29938	11/95	PCT				
	77.	WO 95/08577	03/30/95	WIPO				

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	78.	WO 94/13804	06/23/94	WIPO				
	79.	WO 93/17044	09/02/93	PCT				
	80.	WO 93/15210	08/05/93	WIPO				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	81.	Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site," *Proc. Natl. Acad. Sci. USA*, 88:7978-7982, (1991).
	82.	Bianchi, et al., "Affinity Purification of a Difficult-Sequence Protein: Implications for the Inclusion of Capping in Synthetic Protocols." *Int. J. Pept. Protein Res.*, 42(1):93-96, July 1993.
	83.	Bianchi, et al., "Chemical Synthesis of a Designed Beta-Protein Through the Flow-Polyamide Method" *Int. J. Pept. Protein Res.*, 41(4):385-393, April 1993,
	84.	Bichko et al., "Epitopes recognized by antibodies to denatured core protein of hepatitis B virus," *Mol. Immunol.*, 30(3):221-231, (1993).
	85.	Brett et al., "The invasin protein of Yersinia spp. provides co-stimulatory activity to human T cells through interaction with beta 1 integrins," *Eur. J. Immunol.*, 23(7):1608-1614 (1993).
	86.	Cello J, et al., "Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides," *J. Clin. Microbiol.*, 31(4):911-916 (1993).
	87.	Chien et al., "Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides," *Proc. Natl. Acad. Sci. USA*, 88:9578-9582 (1991).
	88.	Chui et al., "Genetic remodeling of protein glycosylation in vivo induces autoimmune disease," PNAS, 98(3):1142-1147 (2001).
	89.	Cohen, J, et al., "Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes," *Proc Natl Acad Sci USA*, 87(13):4922-4926 (1990).
	90.	Colberre-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells," *J. Molecular Biology*, 150:1-14 (1981).
	91.	Database Genseq 'Online! July 1, 1993, Cytel Corp: "Cytotoxic T-lymphocyte inducing peptide 802.03." XP002183675, Accession AAR33488.
	92.	Database Genseq 'Online! January 8, 1993, Clonatec SA: "Hepatitis B virus HBc antigen II", XP002183674, Accession AAR25272 (published in EP494825).
	93.	Database Genseq 'Online! July 31, 2000, Yeda Res & Dev Co Ltd: "Murine anti-Pab-421 IDI-1 mAb heavy chain CDR based Peptide IDI-H1", XP002183676, Accession AAY70799 (published in WO0023082).
	94.	Database Genseq 'Online! October 21, 1991, Asahi Chemical Ind. KK: "L-chain variable region of plasminogen activator antibody" XP002183673, Accession AAP61027 (published in JP11729000).
	95.	Database Patent_PRT 'Online! March 21, 2001, Eurodiagnostica AB: "Sequence 9 from Patent WO0116163", XP002183677, Accession AX 090806.
	96.	Database WPI, Section Ch, Week 199713, Derwent Publications Ltd., London, GB; Class B04, AN 1997-140911, XP002183678 & JP 09 020798 A (Asahi Kasei Kogyo KK), January 21, 1997, abstract.
	97.	Doolittle R.F. et al., "The Amino Acid Sequence of the α-Chain of Human Fibrinogen," (1979) *Nature*, Vol. 280, pg. 464-468.

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	98.	Felding-Habermann et al., "Role of ß3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow," *J. Biol. Chem.*, 271(10):5892-5900 (1996).
	99.	Flock, "Extracellular-Matrix-Binding Proteins as Targets for the Prevention of Staphylococcus Aureus Infections," (1999) *Molecular Medicine Today*, Vol. 5 pp 532-537.
	100.	Ganem, "Hepadnaviridae and Their Replication," *Fields Virology*, Third Ed., Ch. 85, pp. 2703-2705, 1996.
	101.	GenCore sequence alignment of SEQ ID NO: 16 with the L-chain variable region of plasminogen activator antibody of JP61172900-A, Ashi Chemical Ind. KK. 4/8/1986, ID NO: p. 61027.
	102.	GLYCOPROTEINS, http://www.cs.stedwards.edu/chem/Chemistry/CHEM43/CHEM43/Glycoproteins/Glycopro.
	103.	GLYCOPROTEINS, http://www.users.rcn.com/jkimball.ma.ultrnet/BiologyPages/G/Glycoproteins.html.
	104.	Grabowska et al., "Identification of type-specific domains within glycoprotein G of herpes simplex virus 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1," *Journal of General Virology*, 80(7):1789-1798 (1999).
	105.	Greenspan et al., "Defining epitopes: It's not as easy at it seems," *Nature Biotechnology,* Vol. 17, pp. 936-937, October 1999.
	106.	Haseltine "Replication and Pathogenesis of the AIDS Virus," *Journal of Acquired Immune Deficiency Syndromes*, 1(3):217-240 and 231-236, (1988).
	107.	Henschen A. et al., "Preliminary Note on the Completion of the β-Chain Sequence", (1997) *Z. Physiol. Chem.*, 358:1643-1646.
	108.	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," *Proc Natl. Acad. Sci. USA*, 90:6444-6448, July 1993.
	109.	Huse et al., "Generation of a large combinatorial library of the immunologlobulin repertoire in Phage Lambda," *Science*, 246:1275-1281 (1989).
	110.	Jin et al., "Expression, Isolation, and Characterization of the Hepatitis C Virus ATPase/RNA Helicase," *Archives of Biochemistry and Biophysics*, 323:47-53 (1995).
	111.	Katada et al., "A Novel Peptide Motif for Platelet Fibrinogen Receptor Recognition," *J. Biol. Chem.*, 272(12):7720-7726 (1997).
	112.	Korba and Gerin, "Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication," *Antiviral Res.*, 19(1):55-70 (1992), ABSTRACT ONLY.
	113.	Korba and Milman, "A cell culture assay for compounds which inhibit hepatitis B virus replication," *Antiviral. Res.*, 15(3):217-228 (1991).
	114.	Kreitman et al., "Immunotoxins for targeted cancer therapy," *Advanced Drug Delivery Reviews*, 31:53-88 (1998).
	115.	Lazdina et al., *Journal of Virology*, 75(14):6367-6374, July 2001.
	116.	Leanna & Hannink, "The reverse two-hybrid system: a genetic scheme for selection against specific protein/protein interactions," *Nucl. Acid. Res.*, 24(17):3341-3347 (1996).
	117.	Lee et al., "Predominant Etiologic Association of Hepatitis C Virus with Hepatocellular Carcinoma Compared with Hepatitis B Virus in Elderly Patients in a Hepatitis B-Endemic Area," *Cancer*, 72:2564-2567 (1993).
	118.	Levi et al., "A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodificiency Virus Type 1 *in vitro*," *Proc. Natl. Acad. Sci. USA*, 90: 4374-4378, May 1993.
	119.	Lew et al., "Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions," *Vaccine*, England, Vol. 18, No. 16, pp. 1681-1685 (2000).

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	120.	Li et al., "Adenovirus-mediated expression of pig α(1,3) galactosyltransferase reconstructs Gal α(1, 3) Gal epitope on the surface of human tumor cells," *Cell Research*, 11(2):116-124 (2001), http://www.cell-research.com/20012/01-2-xl.html.
	121.	Lottspeich F. et al., "Preliminary Note on the Completion of the γ-Chain Sequence," (1977) *Z. Physiol. Chem.*, 358:935-938.
	122.	Lowman HB, "Bacteriophage display and discovery of peptide leads for drug development," *Annu. Rev. Biophys. Biomol. Struct.*, 26:401-424 (1997).
	123.	Machida A, et al., "Antigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigen," *Mol. Immunol.*, 26(4):431-421 (1989).
	124.	McDevvit et al., "Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen," *Eur. J. Biochem.*, 247(1):416-424 (1997).
	125.	McDevitt et al., "Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureaus," *Molecular Microbiology*, 16(5):895-907 (1995).
	126.	Milich et al., "Role of B cells in antigen presentation of the hepatitis B core," *Proc. Natl. Acad. Sci. USA*, 94:14648-14653, 1997.
	127.	Milich et al., "The humoral immune response in acute and chronic hepatitis B virus infection," *Springer Semin. Immunopathol.*, 17:149-166 (1995).
	128.	Milich et al., "The Nucleocapsid of Hepatitis B Virus is Both a T-Cell-Independent and a T-Cell-Dependent Antigen," *Science*, 234:1398-1401 (1986).
	129.	Mollick et al., "Localization of a Site on Bacterial Superantigens That Determines T Cell Receptor ∃ Chain Specificity," *J. Exp. Med.*, 177:283-293 (1993).
	130.	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," *Proc. Natl. Acad. Sci. USA*, 81(21):6851-6855 (1984).
	131.	Neuberger et al., "Recombinant antibodies possessing novel effector functions," *Nature*, 312:604-608 (1984).
	132.	Ogg et al., "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes," *British Journal of Cancer*, 82(5):1058-1062 (2002).
	133.	Owens et al., "Mapping the Collagen-Binding Site of Human Fibronectin by Expression in Escherichia Coli," *Embo Journal*, IRL Press, Eynsham, GB, Vol. 5, No. 11, pp. 2825-2830 (1986).
	134.	Pei et al., "Functional Studies of a Fibrinogen Binding Protein from Staphylococcus Epidermidis," (1999) *Infection and Immunity*, p 4525-4530.
	135.	Prange et al., "Chaperones involved in hepatitis B virus morphogenesis," *Biol. Chem.*, Mar. 1999, 380(3):305-314.
	136.	Ramberg, "The Nutrition Science Site: Glyconutritionals," http://glycoscience.com/glycoscience/document_viewer.wm?&ID=719 (2000).
	137.	Randall et al., "High-throughput Chemistry toward Complex Carbohydrates and Carbohydrate-like Compounds[a]," http://www.bentham.org/sample-issues/cchts5-2/arya/arya-ms.htm.
	138.	Roivanen et al., "Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique," *Virology*, 180:99-107 (1991).
	139.	Rudd et al., "Glycosylation and the Immune System," *Science*, 291:2370-2376 (2001) http://sciencemag.org.
	140.	Rudd et al., "The role of glycosylation in the immune system and inflammation," *Research Groups-Dept. of Biochemistry, Oxford*, http://www.bioch.ox.ac.uk/rgroups/rgroupsnew.asp?Group_ID=40.

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	141.	Rüther and Müller-Hill, "Easy identification of cDNA clones," *EMBO Journal*, 2(10):1791-1794 (1983).
	142.	Salfeld J, et al., "Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus," *Journal of Virology*, 63(2):798-808 (1989).
	143.	Sällberg et al., "Characterization of a linear binding site for a monoclonal antibody to hepatitis B core antigen," *J. Med. Virol.*, 33(4):248-252 (1991).
	144.	Sällberg et al., "Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant," *Mol. Immunol.*, 28(7):719-726 (1991).
	145.	Sällberg et al., "Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences," *Journal of General Virology*, 74: 1335-1340, 1993.
	146.	Sällberg et al., *Peptides: Chemistry and Biology,* pp. 715-718, 1993.
	147.	Sällberg et al., "Rapid 'tea-bag' peptide synthesis using 9-fluorenylmethoxcarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins," *Immunology Letters*, 30:59-68, 1991.
	148.	Sällberg et al., "Synthetic peptides as mini antibodies," **Peptides: Chemistry and Biology**, eds. Hodges, R. and J. Rivier, ESCOM, Leiden, pp. 715-718 (1993).
	149.	Sällberg et al., "The Antigen/Antibody Specificity Exchanger: A New Peptide Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120," *Biochemical and Biophysical Research Communications*, 205:1386-1390 (1994).
	150.	Sällberg, M. "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathogen," **U.S. Patent Application** Serial Number 09/664,945, Filed September 19, 2000.
	151.	Sallberg, M., "Ligand/Receptor Specificity Exchangers that Redirect Antibodies to Receptors on a Pathogen," **U.S. Patent Application** Serial Number 09/664,025, Filed September 19, 2000.
	152.	Sällberg, M. "Synthetic Peptides That Bind to the Hepatitis B Virus Core and E Antigens," **U.S. Patent Application** Serial Number 10/153,271, Filed May 21, 2002.
	153.	Saragovi, et al., "Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region" *Science*, 253: 792-795, August 16, 1991.
	154.	Schödel, et al., "Structure of Hepatitis B Virus Core and e-Antigen," *The Journal of Biological Chemistry*, 268:1332-1337, 1993.
	155.	Sears et al., "Toward Automated Synthesis of Oligosaccharides and Glycoproteins," *Science*, Vol. 291, pp. 2344-2350, 03/23/01, http://www.sciencemag.org.
	156.	Sequence alignment of Genseq sequence alignment of instant SEQ ID NO: 28 with the anithuman parathyroid hormone-related protein of JP04228089-A, Kaneka Corp., August 18, 1992, ID NO: AR27008.
	157.	Sequence alignment of Genseq sequence alignment of instant SEQ ID NO: 29 with anti-DNA antibody 7b3 heavy chain variable region of WO 96/36361-A1, University of Michigan, August 12, 1997, ID NO: AAW04593.
	158.	Sequence alignment of Genseq sequence alignment of instant SEQ ID NO: 33 with anti-proenkephalin antibody PE-19 of WO 9606863-A1, University of Dundee, October 9, 1996, ID NO: AAR91370.
	159.	Signals Magazine: Buzz – Glycosylation Matters 06/06/02, http://www.signalsmag.com/signalsmag.nsf/0/A08BFCD79126B34F88256BCE0011B41A.
	160.	Skrivelis et al., *Scand. J. Immunol.*, 37:637-643, 1993.
	161.	Steinbergs et al., *Proceedings of the Latvian Academy of Sciences*, Section B, 50(2):74-77, 1996.
	162.	Takahashi et al., "Acute hepatitis in rates expressing human hepatitis B virus transgenes," *Proc. Natl. Acad. Sci. USA*, 92:1470-1474 (1995).
	163.	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," *Nature*, 314:452-454 (1985).

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. TRIPEP.056A	APPLICATION NO. 10/773,628
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Matti Sällberg	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE February 5, 2004	GROUP Unassigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	164.	Taub R. et al., "A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen," *J. Biol. Chem.*, 264(1):259-265 (1989).
	165.	The Columbia Encyclopedia, Sixth Edition, Copyright 2002, Columbia University Press, http://www.bartleby.com/65/gl/glycopro.html.
	166.	Tramontano et al., "The Making of the Minibody: An Engineered Beta-Protein for the Display of Conformationally Constrained Peptides," *J. of Molecular Recognition*, 7(1): 9-24 (1994).
	167.	Watt K.W.K. et al., "Amino Acid Sequence Studies on the α Chain of Human Fibrinogen Overlapping Sequences Providing the Complete Sequence," (1979) *Biochemistry*, Vol. 18, pp 5410-5416.
	168.	Watt K.W.K. et al., "Amino Acid Sequence of the β Chain of Human Fibrinogen," *Biochemistry*, Vol. 18, pp 68-76.
	169.	Williams et al., "Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity," *J. Biol. Chem.*, 266(8):5182-5190 (1991).
	170.	Williams et al., "Development of biologically active peptides based on antibody structure," *Proc. Natl. Acad. Sci. USA*, 86(14):5537-5541 (1989).
	171.	Winter and Milstein, "Man-made antibodies," *Nature*, 349(6307):293-299 (1991).
	172.	P.R. Wood, H.-F. Seow, "T cell cytokines and disease prevention," *Veterinary Immunology and Immunopathology*, 54(1996) pp. 33-44.
	173.	Zanetti M., "Antigenized Antibodies" *Nature*, 355: 476-477, January 30, 1992.
	174.	Zhang et al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," *Clin. Diagn. Lab. Immunol.*; 7(1):58-63 (2000).
	175.	Zhang et al., "Molecular basis for antibody cros-reactivity between the hepatitis C virs core protein and the hos-derived GOR protein," *Clin. Exp. Immunol.*, 96(3):403-409 (1994).

S:\DOCS\ESF\ESF-7636.DOC
031704

EXAMINER	DATE CONSIDERED

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.